Skip to main content

Aclaris Therapts(ACRS-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time

Aclaris Therapeutics Provides R&D Update

Globe Newswire - Tue Jan 11, 2022

WAYNE, Pa., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today provides an update on the status of certain of its clinical programs and on its research and development (R&D) operations.

Read more at globenewswire.com

Provided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.

More from The Globe

opinion
Four reasons why wealthy investors should hold farmland in their portfolios
Andrea Gruza